SUMMARY
Especially at low to moderate reproductive numbers, the generally mild, non-specific symptomology of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) allows long, thin transmission chains to go undetected by passive surveillance over several weeks. This phenomenon has important implications: (1) Surveillance becomes less sensitive and reliable as an indicator of freedom from infection at the low reproductive numbers required to achieve elimination end points, passive surveillance systems may need to document an absence of new cases for at least a month to establish certainty of elimination. (2) Reproductive numbers should be kept as low as possible throughout such follow up periods without confirmed cases, to ensure such long, thin, undetected transmission chains all collapse before restrictions are eased and reproduction numbers are allowed to rebound. (3) While contact tracing systems may be highly effective when applied to large clusters in foci of elevated transmission where wide, rapidly expanding transmission chains are detected within two viral generations, large fractions of community transmission occurring through thinner, more extended transmission chains at lower reproductive numbers are often be too long to trace retrospectively and will be underrepresented in surveillance data. (4) Wherever surveillance systems are weak and/or younger age groups with lower rates of overt symptoms dominate transmission, containment effectiveness of contact tracing and isolation may be more severely limited, even at the higher reproduction numbers associated with larger outbreaks. While, contact tracing and isolation will remain vital for at least partially containing larger outbreaks, containment and elimination of SARS-CoV-2 will have to rely primarily upon the more burdensome and presumptive population-wide prevention measures that have proven so effective thus far against community transmission. Furthermore, these will have to be sustained at a much more stringent level and for longer periods after the last detected case than was necessary for SARS-CoV-1.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author is supported by an AXA Research Chair award provided to University College Cork by the AXA Research Fund
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All simulations provided in a supplementary file
